TICKERNERD
Menu
HTFLHTFLHealthcare · Health Information Services

HTFL Stock Forecast: HeartFlow, Inc. Price Predictions for 2026-2027

Last close, 17 Sept 2026
$50
+2.63% on the day

The 10 Wall Street analysts covering HeartFlow, Inc. hold a median 12-month price target of $45 — -9.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 17 Sept 2026 — in the lower half.

Market cap
$4.2B
Ticker Nerd rank
48 / 100
Median analyst target
$45
Analysts covering
10
Revenue$64.1M+47.6% y/y
Operating income−$17.9M
Net income−$15.7M
Free cash flow−$10.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+9.0%
1M
+18.2%
YTD
+70.1%
1Y
+56.1%
From 52W high
−1.7%
From 52W low
+141.9%
$20
$50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HTFL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores HeartFlow, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Sept 2026
48 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
95
Momentum
75
Issuance
70
Accruals
58
Value
38
Quality
37
Size
26
Volatility
12
Growth
8

Revisions (95): Analysts have, on balance, been raising their forecasts.

Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HTFL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HTFL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26HTFLHigh $55Median $45Low $39

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
8 Buy2 Hold0 Sell
Low $39Median $45High $55

The green dot is the last close — the median target sits −9.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
9 Sept 2026UBSInitiatesNeutral$55
14 Aug 2026Canaccord GenuityMaintainsBuy$37 → $45
14 Aug 2026Canaccord GenuityMaintainsBuy—
14 Aug 2026JP MorganMaintainsOverweight—
14 Aug 2026JP MorganMaintainsOverweight$35 → $45
14 Aug 2026Morgan StanleyMaintainsEqual-Weight$35 → $40
14 Aug 2026Morgan StanleyMaintainsEqual-Weight—
14 Aug 2026Piper SandlerReiteratesOverweight—
14 Aug 2026Piper SandlerReiteratesOverweight$38 → $45
14 Aug 2026StifelMaintainsBuy$40 → $45
14 Aug 2026StifelMaintainsBuy—
14 Aug 2026Wells FargoMaintainsOverweight—
14 Aug 2026Wells FargoMaintainsOverweight$37 → $39
31 July 2026BairdInitiatesOutperform$34
31 July 2026BairdInitiatesOutperform—
1 July 2026Freedom Capital MarketsInitiatesBuy$37
1 July 2026Freedom Capital MarketsInitiatesBuy—
15 May 2026Canaccord GenuityMaintainsBuy—
15 May 2026Wells FargoMaintainsOverweight—
4 May 2026William BlairInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HTFL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

HTFL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Sept 2026, HeartFlow, Inc. returned +56.1% against +17.0% for the S&P 500, dividends included.

HTFL vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Oct 25Jan 26Apr 26Jul 26HTFLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HTFL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
0
Fundamentals

HeartFlow, Inc. (HTFL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−15.2×

Cheaper than 95% of US stocks

Price / sales
19.8×

Cheaper than 9% of US stocks

Price / book
15.0×

Cheaper than 6% of US stocks

EV / EBITDA
−57.0×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
47.6%

Higher than 85% of US stocks

Earnings growth (YoY)
47.6%

Higher than 73% of US stocks

Gross margin
83.0%

Higher than 93% of US stocks

Operating margin
−27.9%

Higher than 20% of US stocks

Net margin
−55.8%

Higher than 9% of US stocks

Returns & dividend
Return on equity
−154.2%

Higher than 9% of US stocks

Return on assets
−18.1%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

HeartFlow, Inc. (HTFL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • HeartFlow, Inc. has a market value of $4.2B and an enterprise value of $4.1B.

  • Revenue in the twelve months to 30 June 2026: $212.1M. The latest quarter grew 47.6% year on year.

  • Net income over the same four quarters: −$118.4M, a −55.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.83.

  • Free cash flow in the twelve months to 30 June 2026: −$59.2M.

  • Shares outstanding: 86.7M.

  • Trailing P/E: −15.2×; forward P/E: −187.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • HeartFlow, Inc. employs 843 people — $252K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 16 Sept 2026

Data provided by Twelve Data

Peers

HTFL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
HTFLHeartFlow, Inc.$4.2B
48
DOCSDoximity, Inc.$4.9B
61
WAYWaystar Holding Corp.$5.1B
34
PRVAPrivia Health Group, Inc.$2.5B
66
HNGEHinge Health, Inc.$7.3B
79
SDGRSchrödinger, Inc.$2.3B
55
HQYHealthEquity, Inc.$8.1B
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own HeartFlow, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HTFL news & analysis

HeartFlow's CEO Sells 38,900 Shares for $1.8 Million After the Stock Hit a 52-Week High

The Motley Fool · 15 Sept 2026neutral

HeartFlow's CEO sold 38,900 shares for approximately $1.8 million at a weighted average price of $46.78 per share, representing 11% of the executive's pre-filing equity stake, after the stock reached a 52-week high.

Why it matters — Insider selling by a CEO after a stock hits a 52-week high can draw investor attention to whether the move signals the executive's view on the company's valuation.

HeartFlow CFO Dumps Over 33,000 Shares for $1.7 Million as the Stock Hits a 52-Week High

The Motley Fool · 6 Sept 2026neutral

HeartFlow's CFO sold 33,416 shares of the company for approximately $1.7 million, at a weighted average price of $49.85. The sale, which occurred as the stock reached a 52-week high, represented 13% of the officer's pre-transaction equity stake.

Why it matters — HTFL watchers would care because insider selling at a 52-week high can signal the executive's view of the stock's valuation.

Baron SMID Cap ETF Q2 2026 Portfolio Activity

Seeking Alpha · 4 Sept 2026negative

Baron SMID Cap ETF sold its HeartFlow position during Q2 2026. The fund stated it grew incrementally more concerned with the presence of competitors on the market.

Why it matters — A notable fund manager divesting its HeartFlow stake over competitive concerns signals growing investor wariness about competitive pressure on the company.

Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half

GlobeNewsWire · 28 Aug 2026positive

Late-breaking data from the independent, government-funded FUSION trial, presented at the ESC congress and published in the Journal of the American College of Cardiology, showed that HeartFlow's FFRCT analysis reduced unnecessary invasive heart procedures by nearly half. The trial demonstrated that adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty and supports Appropriate Use Criteria for cath lab referrals.

Why it matters — HTFL watchers would care because independent trial evidence reinforcing the clinical value of FFRCT in reducing unnecessary procedures could strengthen the case for broader adoption of the technology.

Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference

GlobeNewsWire · 27 Aug 2026neutral

HeartFlow, Inc. announced that its management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference. The session, featuring a slideshow presentation followed by a Q&A, is scheduled for September 9, 2026, in Boston.

Why it matters — The fireside chat gives HeartFlow watchers visibility into management's views and company updates at a major healthcare investment conference.

FAQ

Frequently asked questions about HTFL stock

What is the HTFL stock price forecast for 2026-2027?

The 10 Wall Street analysts covering HeartFlow, Inc. have a median 12-month price target of $45, with estimates ranging from $39 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HTFL stock a buy right now?

Of the 10 analysts covering HeartFlow, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks HeartFlow, Inc. 48 out of 100 across roughly 4,600 US stocks as at 17 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HTFL?

As at 17 Sept 2026, HeartFlow, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (95 of 100).

Will HTFL stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies -9.2% from the last close, and Ticker Nerd's factor model ranks HeartFlow, Inc. 48 out of 100 as at 17 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HTFL stock forecast for 2030?

No analyst covering HeartFlow, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HTFL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $39 to $55 over the next 12 months.

How has HTFL stock performed over the past year?

HeartFlow, Inc. returned +56.1% over the 12 months to 17 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does HeartFlow, Inc. do?

HeartFlow Inc. is a commercial-stage medical technology company focused on non-invasive coronary artery disease diagnosis and management.

What is the latest news on HTFL?

The most recent item we track (The Motley Fool, 15 Sept 2026): "HeartFlow's CEO Sells 38,900 Shares for $1.8 Million After the Stock Hit a 52-Week High". HeartFlow's CEO sold 38,900 shares for approximately $1.8 million at a weighted average price of $46.78 per share, representing 11% of the executive's pre-filing equity stake, after the stock reached a 52-week high.

Company

About HeartFlow, Inc.

HeartFlow Inc. is a commercial-stage medical technology company focused on non-invasive coronary artery disease diagnosis and management. HeartFlow Inc. develops software and artificial intelligence tools that analyze coronary computed tomography angiography scans to create personalized 3D models of a patient’s heart, helping physicians assess blood flow, stenosis, plaque volume, and plaque composition. Its main products include HeartFlow FFRCT Analysis, Plaque Analysis, and RoadMap Analysis, which support clinical decision-making across the coronary care pathway. The company serves hospitals, cardiology practices, and healthcare systems in the United States and selected international markets, with its platform used to improve precision in cardiovascular assessment and treatment planning. Headquartered in San Francisco, California, HeartFlow Inc. operates at the intersection of medical imaging, digital health, and cardiovascular diagnostics.

CEO Mr. John C.M. Farquhar · 843 employees · United States · https://www.heartflow.com